Anavex Life Sciences Corp (AVXL)

[Joseph_K]

Yes, THIS article is new. And Anavex is in it.

Siddiqui, T., Bhatt, L.K. Targeting Sigma-1 Receptor: A Promising Strategy in the Treatment of Parkinson’s Disease. Neurochem Res (2023). https://doi.org/10.1007/s11064-023-03960-6

See Table 2:

tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73)

Modulation of oxidative stress

• The S1R agonistic activity was studied in Swiss OF-1 mice

• The ANAVEX2-73 attenuated ROS levels generated by pathogenic amyloid ß

• The complex I and IV of ETC was increased suggesting enhanced mitochondrial respiration

• The suggested mechanism could be modulation of ERK pathway or blockade of Ca2?+—activated K?+?(SK) channels

Its reference to Anavex research relates to a 2017 paper* about Anavex molecules in a mouse model. Nothing directly about Anavex Parkinson's clinical trials.

But it's upbeat about the Anavex MOA for use against Parkinson's (though the article more prominently features Prilenia Therapeutics' pridopidine):

Further, S1R agonists modulate gene expression of endogenous antioxidants. All these properties make S1R an ideal therapeutic target for PD.

* https://link.springer.com/article/10.1007/s12640-017-9838-2